Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Eur J Clin Microbiol Infect Dis ; 37(4): 661-663, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29214504

ABSTRACT

Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make this an appropriate target for applying a nonspecific antimicrobial therapeutic. Taurolidine hydrolyzes into two antimicrobial moieties, formaldehyde and methylene glycol, which react with microbial surfaces. Neutrolin® (taurolidine, heparin, calcium citrate) was recently introduced in Germany as an antimicrobial catheter lock solution. This postmarketing experience collected data on 201 patients at 20 centers from January 2014 through September 2016. Likely CRBSI was observed in 13 episodes in 47,118 days (0.2759 per 1000 days [0.1468, 0.4718]). Thrombosed catheter was observed in seven catheters in 47,118 days (0.1486 per 1000 days [0.0595, 0.3061]). No adverse drug reactions that led to the discontinuation of Neutrolin® use were reported. Two patients experienced occasional transient dysgeusia. Neutrolin®, when used in conjunction with guideline-based catheter care, showed reduction in the rate of both CRBSI and catheter thrombosis relative to recent historical controls.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Calcium Citrate/therapeutic use , Catheter-Related Infections , Central Venous Catheters , Heparin/therapeutic use , Product Surveillance, Postmarketing , Renal Dialysis , Taurine/analogs & derivatives , Thiadiazines/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Calcium Citrate/administration & dosage , Calcium Citrate/adverse effects , Catheter-Related Infections/drug therapy , Catheter-Related Infections/epidemiology , Catheter-Related Infections/prevention & control , Drug Combinations , Germany/epidemiology , Heparin/administration & dosage , Heparin/adverse effects , Humans , Taurine/administration & dosage , Taurine/adverse effects , Taurine/therapeutic use , Thiadiazines/administration & dosage , Thiadiazines/adverse effects , Thrombosis/drug therapy , Thrombosis/epidemiology , Thrombosis/prevention & control
2.
Oxid Med Cell Longev ; 2017: 4353462, 2017.
Article in English | MEDLINE | ID: mdl-28337251

ABSTRACT

Objective. Oxidative stress and endothelial dysfunction contribute to pulmonary arterial hypertension (PAH). The role of the nitrovasodilator pentaerythritol tetranitrate (PETN) on endothelial function and oxidative stress in PAH has not yet been defined. Methods and Results. PAH was induced by monocrotaline (MCT, i.v.) in Wistar rats. Low (30 mg/kg; MCT30), middle (40 mg/kg; MCT40), or high (60 mg/kg; MCT60) dose of MCT for 14, 28, and 42 d was used. MCT induced endothelial dysfunction, pulmonary vascular wall thickening, and fibrosis, as well as protein tyrosine nitration. Pulmonary arterial pressure and heart/body and lung/body weight ratio were increased in MCT40 rats (28 d) and reduced by oral PETN (10 mg/kg, 24 d) therapy. Oxidative stress in the vascular wall, in the heart, and in whole blood as well as vascular endothelin-1 signaling was increased in MCT40-treated rats and normalized by PETN therapy, likely by upregulation of heme oxygenase-1 (HO-1). PETN therapy improved endothelium-dependent relaxation in pulmonary arteries and inhibited endothelin-1-induced oxidative burst in whole blood and the expression of adhesion molecule (ICAM-1) in endothelial cells. Conclusion. MCT-induced PAH impairs endothelial function (aorta and pulmonary arteries) and increases oxidative stress whereas PETN markedly attenuates these adverse effects. Thus, PETN therapy improves pulmonary hypertension beyond its known cardiac preload reducing ability.


Subject(s)
Endothelin-1/metabolism , Oxidative Stress/drug effects , Pentaerythritol Tetranitrate/pharmacology , Vasodilator Agents/pharmacology , Acetylcholine/metabolism , Animals , Blood Pressure/drug effects , Body Weight/drug effects , Cell Line , Echocardiography , Endothelin-1/genetics , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Heart/diagnostic imaging , Heme Oxygenase-1/genetics , Heme Oxygenase-1/metabolism , Humans , Hypertension, Pulmonary/chemically induced , Hypertension, Pulmonary/drug therapy , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Male , Monocrotaline/toxicity , Pentaerythritol Tetranitrate/therapeutic use , Rats , Rats, Wistar , Signal Transduction/drug effects , Up-Regulation/drug effects
3.
Eur Heart J ; 35(14): 895-903, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24071762

ABSTRACT

BACKGROUND: The organic nitrate pentaerithrityl tetranitrate (PETN) has been shown to have ancillary properties that prevent the development of tolerance and endothelial dysfunction. This randomized, double-blind, placebo-controlled, multicentre study ('CLEOPATRA' study) was designed to investigate the anti-ischaemic efficacy of PETN 80 mg b.i.d. (morning and mid-day) over placebo in patients with chronic stable angina pectoris. METHODS AND RESULTS: A total of 655 patients were evaluated in the intention-to-treat population, randomized to PETN (80 mg b.i.d., n = 328) or placebo (n = 327) and completed the study. Patients underwent treadmill exercise tests at randomization, after 6 and 12 weeks of treatment. Treatment with PETN over 12 weeks did not modify the primary endpoint total exercise duration (TED, P = 0.423). In a pre-specified sub-analysis of patients with reduced exercise capacity (TED at baseline ≤9 min, n = 257), PETN appeared more effective than placebo treatment (P = 0.054). Superiority of PETN over placebo was evident in patients who were symptomatic at low exercise levels (n = 120; P = 0.017). Pentaerithrityl tetranitrate 80 mg b.i.d. was well tolerated, and the overall safety profile was comparable with placebo. CONCLUSION: Although providing no additional benefit in unselected patients with known coronary artery disease, PETN therapy, administered in addition to modern anti-ischaemic therapy, could increase exercise tolerance in symptomatic patients with reduced exercise capacity.


Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Angina, Stable/drug therapy , Pentaerythritol Tetranitrate/administration & dosage , Vasodilator Agents/administration & dosage , Adrenergic beta-Antagonists/therapeutic use , Chronic Disease , Delayed-Action Preparations , Double-Blind Method , Exercise Test , Exercise Tolerance/drug effects , Female , Humans , Male , Medication Adherence , Middle Aged , Treatment Outcome
4.
Clin Res Cardiol ; 101(6): 453-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22298019

ABSTRACT

INTRODUCTION: Ischemic and pharmacologic preconditioning have great clinical potential, but it remains unclear whether their effects can be maintained over time during repeated exposure.We have previously demonstrated that the acute protective effect of nitroglycerin (GTN) is attenuated during repeated daily administration. Pentaerythrityl tetranitrate (PETN) is an organic nitrate with different hemodynamic and biochemical properties. The purpose of the current experiment was to study the preconditioning-like effects of PETN and GTN during repeated daily exposure. METHODS AND RESULTS: In a randomized, investigator-blind parallel trial, 30 healthy (age 25-32) volunteers were randomized to receive (1) transdermal GTN (0.6 mg/h) administered for 2 h a day for 6 days; (2) oral PETN (80 mg) once a day for 6 days; or (3) no therapy. One week later, endothelium-dependent flow-mediated dilation was assessed before and after exposure to ischemia and reperfusion (IR). IR caused a significant blunting of the endothelium-dependent relaxation in the control group (FMD before IR: 5.8 ± 2.1%; after IR 1.0 ± 2.1%; P < 0.01). Daily, 2-h exposure to GTN partially prevented IR-induced endothelial dysfunction (FMD before IR: 7.7 ± 2.4%; after IR 4.3 ± 3.0%; P < 0.01 compared to before IR). In contrast, daily PETN administration afforded greater protection from IR-induced endothelial injury (FMD before IR: 7.9 ± 1.7%; after IR 6.4 ± 5.3%, P = ns; P < 0.05 ANOVA across groups). In vitro, incubation of human endothelial cells with GTN (but not PETN) was associated with inhibition (P < 0.01) of aldehyde dehydrogenase, an enzyme that is important for both nitrate biotransformation and ischemic preconditioning. DISCUSSION: We previously showed that upon repeated administration, the preconditioning-like effects of GTN are attenuated. The present data demonstrate a gradient in the extent of protection afforded by the two nitrates, suggesting that PETN-induced preconditioning is maintained after prolonged administration in a human in vivo model of endothelial dysfunction induced by ischemia. Using isolated human endothelial cells, we propose a mechanistic explanation for this observation based on differential effects of GTN versus PETN on the activity of mitochondrial aldehyde dehydrogenase.


Subject(s)
Ischemic Preconditioning/methods , Nitroglycerin/pharmacology , Pentaerythritol Tetranitrate/pharmacology , Reperfusion Injury/drug therapy , Adult , Aldehyde Dehydrogenase/antagonists & inhibitors , Analysis of Variance , Cells, Cultured , Drug Administration Schedule , Endothelium, Vascular/drug effects , Endothelium, Vascular/pathology , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Nitroglycerin/administration & dosage , Pentaerythritol Tetranitrate/administration & dosage , Reperfusion Injury/physiopathology , Single-Blind Method , Vasodilator Agents/administration & dosage , Vasodilator Agents/pharmacology
5.
J Pharmacol Exp Ther ; 330(1): 63-71, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19346443

ABSTRACT

Recent animal data suggest that reduced lipoic acid (LA) prevents oxidative inhibition of the nitrate bioactivating enzyme, the mitochondrial aldehyde dehydrogenase (ALDH-2), and that pentaerythritol tetranitrate (PETN) does not induce nitrate tolerance because of its intrinsic antioxidative properties, thereby preserving ALDH-2 activity. We sought to determine whether ALDH-2 activity in circulating white blood cells (WBCs) can be used to monitor nitrate tolerance and whether LA can prevent nitroglycerin tachyphylaxis in humans. Eight healthy male volunteers received, in randomized order, a single dose of glyceryl trinitrate (GTN; 0.8 mg), PETN (80 mg), or GTN plus LA (600 mg) orally. GTN (30 min) and PETN (120 min) administration lead to a comparable dilation of the brachial artery (15 +/- 1%). In contrast to PETN, acute GTN treatment resulted in a 60% decrease in WBC ALDH-2 activity (high-performance liquid chromatography), 30% reduction of nitrate bioactivation, and 25% decrease in serum antioxidant capacity (fluorescence assay), which all were prevented by pretreatment with LA. Mechanistic studies in rats identified oxidative stress, ALDH-2 inactivation, and vascular dysfunction as common features in acute and chronic nitrate tolerance. Treatment with GTN, but not PETN, acutely inhibits ALDH-2 activity and nitrate bioactivation in healthy volunteers. These effects were prevented by LA pretreatment, emphasizing the role of oxidative stress-triggered ALDH-2 dysfunction. Assessment of WBC ALDH-2 activity could be used as an easily accessible marker for the detection of nitroglycerin-induced tachyphylaxis in humans and may be of high clinical interest because recent data suggest that ALDH-2 activity correlates with protection from ischemic heart damage in infarct models.


Subject(s)
Aldehyde Dehydrogenase/metabolism , Leukocytes/enzymology , Mitochondria, Heart/enzymology , Nitrates/therapeutic use , Aldehyde Dehydrogenase/antagonists & inhibitors , Animals , Enzyme Activation/drug effects , Enzyme Activation/physiology , Humans , Leukocytes/drug effects , Male , Mitochondria, Heart/drug effects , Myocardial Ischemia/drug therapy , Myocardial Ischemia/enzymology , Nitrates/pharmacology , Rats , Rats, Wistar , Vasodilation/drug effects , Vasodilation/physiology
6.
J Cardiovasc Pharmacol ; 50(1): 68-74, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17666918

ABSTRACT

Neither therapeutic dosage of nitrovasodilators nor the development of tolerance correlates with nitrate groups in these molecules. Clinically, low dosages of glyceryl trinitrate (GTN) develop tolerance, but 100-fold higher dosages of pentaerythrityl tetranitrate (PETN) do not. Vasorelaxation was studied on prostaglandian F2alpha (PGF2alpha)-precontracted porcine pulmonary arteries in organ bath procedure. In vitro tolerance was induced by incubating the arteries with different nitrate concentrations and thereafter concentration-response curves were repeated. Furthermore, 14 mg/kg PETN were daily administered to rats by gavage; PETN and metabolites were measured in feces and blood. In vitro, the vasodilator potencies increased from mononitrates to tetranitrates (pD2: 4.14 to 8.18); PETN was the most potent vasodilator. In vitro tolerance was found with PETN and trinitrates but not with dinitrates and mononitrates. Thus, in vitro tolerance correlated with the in vitro potency of nitrates but not with the vasodilator potency of NO donors in general, because S-nitroso-N-aectyl-D-penicillamine and N-phenylpiperazin-NONOate were more potent than GTN but did not induce tolerance. After feeding of rats with PETN, pentaerythrityl dinitrate (PEdiN) and mononitrate (PEmonoN) but neither PETN nor PEtriN (both detected in feces) were found in the blood. The missing systemic bioavailability of PETN and PEtriN may explain the discrepancy between in vitro and in vivo findings. We conclude that the partially denitrated metabolites PEdiN and PEmonoN contribute to the moderate and tolerance-devoid clinical activity of PETN.


Subject(s)
Drug Tolerance , Pentaerythritol Tetranitrate/pharmacology , Vasodilation/drug effects , Vasodilator Agents/pharmacology , Animals , Biological Availability , Dinoprost , Dose-Response Relationship, Drug , Male , Nitrates/pharmacology , Nitric Oxide Donors/pharmacology , Pentaerythritol Tetranitrate/administration & dosage , Pentaerythritol Tetranitrate/pharmacokinetics , Pulmonary Artery , Rats , Rats, Wistar , Swine , Vasodilator Agents/administration & dosage , Vasodilator Agents/pharmacokinetics
7.
Arterioscler Thromb Vasc Biol ; 27(8): 1729-35, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17541025

ABSTRACT

OBJECTIVE: Nitrate tolerance is likely attributable to an increased production of reactive oxygen species (ROS) leading to an inhibition of the mitochondrial aldehyde dehydrogenase (ALDH-2), representing the nitroglycerin (GTN) and pentaerythrityl tetranitrate (PETN) bioactivating enzyme, and to impaired nitric oxide bioactivity and signaling. We tested whether differences in their capacity to induce heme oxygenase-1 (HO-1) might explain why PETN and not GTN therapy is devoid of nitrate and cross-tolerance. METHODS AND RESULTS: Wistar rats were treated with PETN or GTN (10.5 or 6.6 microg/kg/min for 4 days). In contrast to GTN, PETN did not induce nitrate tolerance or cross-tolerance as assessed by isometric tension recordings in isolated aortic rings. Vascular protein and mRNA expression of HO-1 and ferritin were increased in response to PETN but not GTN. In contrast to GTN therapy, NO signaling, ROS formation, and the activity of ALDH-2 (as assessed by an high-performance liquid chromatography-based method) were not significantly influenced by PETN. Inhibition of HO-1 expression by apigenin induced "tolerance" to PETN whereas HO-1 gene induction by hemin prevented tolerance in GTN treated rats. CONCLUSIONS: HO-1 expression and activity appear to play a key role in the development of nitrate tolerance and might represent an intrinsic antioxidative mechanism of therapeutic interest.


Subject(s)
Drug Tolerance , Heme Oxygenase-1/metabolism , Nitroglycerin/pharmacology , Pentaerythritol Tetranitrate/pharmacology , Aldehyde Dehydrogenase/metabolism , Animals , Chromatography, High Pressure Liquid , Cyclic GMP/metabolism , Disease Models, Animal , Endothelium, Vascular/drug effects , Free Radical Scavengers , Heme Oxygenase-1/drug effects , Male , Nitroglycerin/metabolism , Pentaerythritol Tetranitrate/metabolism , Probability , Random Allocation , Rats , Rats, Wistar , Reactive Oxygen Species , Reference Values , Sensitivity and Specificity
8.
BMC Cardiovasc Disord ; 6: 44, 2006 Nov 08.
Article in English | MEDLINE | ID: mdl-17092343

ABSTRACT

BACKGROUND: Chronic therapy with nitroglycerin (GTN) results in a rapid development of nitrate tolerance which is associated with an increased production of reactive oxygen species (ROS). According to recent studies, mitochondrial ROS formation and oxidative inactivation of the organic nitrate bioactivating enzyme mitochondrial aldehyde dehydrogenase (ALDH-2) play an important role for the development of nitrate and cross-tolerance. METHODS: Tolerance was induced by infusion of wild type (WT) and heterozygous manganese superoxide dismutase mice (Mn-SOD+/-) with ethanolic solution of GTN (12.5 mug/min/kg for 4 d). For comparison, the tolerance-free pentaerithrityl tetranitrate (PETN, 17.5 mug/min/kg for 4 d) was infused in DMSO. Vascular reactivity was measured by isometric tension studies of isolated aortic rings. ROS formation and aldehyde dehydrogenase (ALDH-2) activity was measured in isolated heart mitochondria. RESULTS: Chronic GTN infusion lead to impaired vascular responses to GTN and acetylcholine (ACh), increased the ROS formation in mitochondria and decreased ALDH-2 activity in Mn-SOD+/- mice. In contrast, PETN infusion did not increase mitochondrial ROS formation, did not decrease ALDH-2 activity and accordingly did not lead to tolerance and cross-tolerance in Mn-SOD+/- mice. PETN but not GTN increased heme oxygenase-1 mRNA in EA.hy 926 cells and bilirubin efficiently scavenged GTN-derived ROS. CONCLUSION: Chronic GTN infusion stimulates mitochondrial ROS production which is an important mechanism leading to tolerance and cross-tolerance. The tetranitrate PETN is devoid of mitochondrial oxidative stress induction and according to the present animal study as well as numerous previous clinical studies can be used without limitations due to tolerance and cross-tolerance.


Subject(s)
Drug Tolerance , Mitochondria, Heart/metabolism , Nitroglycerin/pharmacology , Oxidative Stress/drug effects , Pentaerythritol Tetranitrate/pharmacology , Superoxide Dismutase/deficiency , Vasodilator Agents/pharmacology , Acetylcholine/pharmacology , Aldehyde Dehydrogenase/metabolism , Aldehyde Dehydrogenase, Mitochondrial , Animals , Aorta/drug effects , Aorta/physiology , Bilirubin/metabolism , Cell Line , Drug Administration Schedule , Free Radical Scavengers/metabolism , Heme Oxygenase-1/genetics , Heterozygote , Humans , In Vitro Techniques , Male , Mice , Nitroglycerin/administration & dosage , RNA, Messenger/metabolism , Rats , Rats, Wistar , Reactive Oxygen Species/antagonists & inhibitors , Superoxide Dismutase/genetics , Vasodilation , Vasodilator Agents/administration & dosage
9.
Mol Pharmacol ; 66(6): 1372-82, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15331769

ABSTRACT

Mitochondrial aldehyde dehydrogenase (ALDH-2) was recently identified to be essential for the bioactivation of glyceryl trinitrate (GTN). Here we assessed whether other organic nitrates are bioactivated by a similar mechanism. The ALDH-2 inhibitor benomyl reduced the vasodilator potency, but not the efficacy, of GTN, pentaerythritol tetranitrate (PETN), and pentaerythritol trinitrate in phenylephrine-constricted rat aorta, whereas vasodilator responses to isosorbide dinitrate, isosorbide-5-mononitrate, pentaerythritol dinitrate, pentaerythritol mononitrate, and the endothelium-dependent vasodilator acetylcholine were not affected. Likewise, benomyl decreased GTN- and PETN-elicited phosphorylation of the cGMP-activated protein kinase substrate vasodilator-stimulated phosphoprotein (VASP) but not that elicited by other nitrates. The vasodilator potency of organic nitrates correlated with their potency to inhibit ALDH-2 dehydrogenase activity in mitochondria from rat heart and increase mitochondrial superoxide formation, as detected by chemiluminescence. In contrast, mitochondrial ALDH-2 esterase activity was not affected by PETN and its metabolites, whereas it was inhibited by benomyl, GTN applied in vitro and in vivo, and some sulfhydryl oxidants. The bioactivation-related metabolism of GTN to glyceryl-1,2-dinitrate by isolated RAW macrophages was reduced by the ALDH-2 inhibitors benomyl and daidzin, as well as by GTN at concentrations >1 microM. We conclude that mitochondrial ALDH-2, specifically its esterase activity, is required for the bioactivation of the organic nitrates with high vasodilator potency, such as GTN and PETN, but not for the less potent nitrates. It is interesting that ALDH-2 esterase activity was inhibited by GTN only, not by the other nitrates tested. This difference might explain why GTN elicits mitochondrial superoxide formation and nitrate tolerance with the highest potency.


Subject(s)
Aldehyde Dehydrogenase/metabolism , Mitochondria, Heart/enzymology , Muscle, Smooth, Vascular/physiology , Nitroglycerin/pharmacology , Oxidative Stress/physiology , Pentaerythritol Tetranitrate/pharmacology , Reactive Oxygen Species/metabolism , Animals , Aorta , Benomyl/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Esterases/metabolism , Ethanol/pharmacology , In Vitro Techniques , Isometric Contraction/drug effects , Isometric Contraction/physiology , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Models, Animal , Muscle, Smooth, Vascular/drug effects , Oxidative Stress/drug effects , Rats , Rats, Wistar , Vasodilator Agents/pharmacology
10.
Exp Biol Med (Maywood) ; 228(5): 529-34, 2003 May.
Article in English | MEDLINE | ID: mdl-12709581

ABSTRACT

Pentaerithrityl tetranitrate (PETN) is a long-acting donor of nitric oxide (NO) and has recently been characterized as an antianginal agent that, in contrast with other nitric acid esters, does not induce oxidative stress and is therefore free of tolerance. Moreover, animal experiments have revealed that PETN actively reduces oxygen radical formation in vivoand specifically prevents atherogenesis and endothelial dysfunction. Because heme oxygenase-1 (HO-1) has been described as an antiatherogenic and cytoprotective gene in the endothelium, our aim was to investigate the effect of the active PETN metabolite pentaerithrityl trinitrate (PETriN) on HO-1 expression and catalytic activity in endothelial cells. Endothelial cells derived from human umbilical vein were incubated with PETriN (0.01-1 mM) for 8 hr. PETriN increased HO-1 mRNA and protein levels in a concentration-dependent fashion up to 3-fold over basal levels. Elevation of HO-1 protein was accompanied by a marked increase in catalytic activity of the enzyme as reflected by enhanced formation of both carbon monoxide and the endogenous antioxidant, bilirubin. Pretreatment of endothelial cells with PETriN or bilirubin at low micromolar concentrations protected endothelial cells from hydrogen peroxide-mediated toxicity. HO-1 induction and endothelial protection by PETriN were not mimicked by isosorbide dinitrate, another long-acting nitrate. The present study demonstrates that the active PETN metabolite, PETriN, stimulates mRNA and protein expression as well as enzymatic activity of the antioxidant defense protein, HO-1, in endothelial cells. Increased HO-1 expression and ensuing formation of bilirubin and carbon monoxide may contribute to and explain the specific antioxidant and antiatherogenic actions of PETN.


Subject(s)
Bilirubin/metabolism , Carbon Monoxide/metabolism , Endothelium, Vascular/drug effects , Heme Oxygenase (Decyclizing)/metabolism , Pentaerythritol Tetranitrate/analogs & derivatives , Pentaerythritol Tetranitrate/pharmacology , Animals , Antioxidants/metabolism , Cell Survival/physiology , Cells, Cultured , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Heme Oxygenase (Decyclizing)/genetics , Heme Oxygenase-1 , Humans , Isosorbide Dinitrate/metabolism , Membrane Proteins , Nitric Oxide Donors/metabolism , S-Nitroso-N-Acetylpenicillamine/metabolism
11.
Biochem Biophys Res Commun ; 290(5): 1539-44, 2002 Feb 08.
Article in English | MEDLINE | ID: mdl-11820797

ABSTRACT

The organic nitrate pentaerythrityl tetranitrate (PETN) is known to exert long-term antioxidant and antiatherogenic effects by as yet unidentified mechanisms. In cultured endothelial cells derived from human umbilical vein, the active PETN metabolite PETriN (0.01-1 mM) increased heme oxygenase (HO)-1 mRNA and protein levels in a concentration-dependent fashion. HO-1 induction was accompanied by a marked increase in catalytic activity of the enzyme as reflected by enhanced formation of carbon monoxide and bilirubin. Pretreatment with PETriN or bilirubin at low micromolar concentrations protected endothelial cells from hydrogen peroxide-mediated toxicity. HO-1 induction and endothelial protection by PETriN were not mimicked by isosorbide dinitrate, another long-acting nitrate. The present study demonstrates that PETriN stimulates mRNA and protein expression as well as enzymatic activity of the antioxidant defense protein HO-1 in endothelial cells. Increased HO-1 expression and ensuing formation of cytoprotective bilirubin may contribute to and explain the specific antioxidant and antiatherogenic actions of PETN.


Subject(s)
Antioxidants/pharmacology , Heme Oxygenase (Decyclizing)/biosynthesis , Pentaerythritol Tetranitrate/pharmacology , Animals , Bilirubin/biosynthesis , Bilirubin/physiology , Catalysis/drug effects , Cell Line , Cell Survival/drug effects , Cell Survival/genetics , Endothelium, Vascular/drug effects , Endothelium, Vascular/enzymology , Heme Oxygenase (Decyclizing)/genetics , Heme Oxygenase-1 , Humans , Membrane Proteins , Pentaerythritol Tetranitrate/analogs & derivatives , Pentaerythritol Tetranitrate/metabolism , RNA, Messenger/biosynthesis , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...